Four child and adult hemophilia medicines have arrived in Ukraine. UNDP and MOH saved another 36 mln of budget HryvniasJan 23, 2018
Four human coagulation factor medicines for treatment of hemophilia in adults and children have arrived in Ukraine. Thanks to efficient procurement process by UNDP, today another 36 mln Hryvnia of state budget funds are already saved through procurement of adult and child hemophilia medicines.
Four medicines for a total amount of 155 mln Hryvnia have arrived in Ukraine. “Human coagulation factor VIII (plasma) (1000 IU)” and “Human coagulation factor VIII and Willebrand factor (1000 IU)” were delivered under adult hemophilia program, while “Human coagulation factor VIII and human von Willebrand factor” (500 IU and 1000 IU) were delivered under child hemophilia program.
According to the signed contracts, UNDP is procuring medicines and medical products for 26 of those programs. At the end of July 2017 UNDP signed with MOH the first agreement for 15 programs, namely:
- treatment of bleeding;
- cancer in adults;
- cystic fibrosis in children;
- cerebral palsy;
- resistant juvenile rheumatoid arthritis;
- prevention of hemolytic disease of the newborn (Anti-D immunoglobulin);
- female infertility treatment by means of assisted reproductive technologies;
- children and adults with hemophilia;
- multiple sclerosis;
- epidermolysis bullosa;
- dwarfism of various origins;
- orphan metabolic diseases;
- Gaucher disease.
Agreements for the remaining 11 programs were signed later during the year. The following programs were added:
- cancer in children;
- viral hepatitis in adults and children;
- pulmonary arterial hypertension;
- treatment and diagnostics of TB;
- neonatal screening for phenylketonuria, congenital hypothyroidism, cystic fibrosis and adrenogenital syndrome;
- patients in pre- and post-transplant period;
- primary (congenital) immunodeficiency;
- children with mental and behavioral disorders of autism spectrum;
- cystic fibrosis in adults;
This year Ministry of Health of Ukraine has widened the list of medicines and included innovative medicines for treatment of cancer in adults, mucopolysaccharidosis, pulmonary arterial hypertension, hemophilia in children and adults and hepatitis in adults and children. Coverage was increased for patients with various diseases.
UNDP reports that procurement for 15 programs signed earlier this year is completed. Medicines are being supplied to the country according to the agreed schedule. Preliminary amount of savings generated for all programs equals to 160 mln UAH. At the moment medicines and medical products were delivered for the amount of 478 mln UAH out of 1,3 bln UAH that are committed in the contracts. Procurement process is being conducted for the rest 11 programs. UNDP has signed a number of long-term agreements with pharmaceutical manufacturers to ensure the fastest delivery of medicines for Ukrainians.
Mr. Janthomas Hiemstra, UNDP Country Director in Ukraine, commented: "UNDP Ukraine has started to use a new, more efficient and cost-saving approach to medicine procurement –long-term agreements with pharmaceutical companies. Signing supply agreements for multiple years, helps Ukrainian patients to have continuous and uninterrupted access to high-quality medicines at the most competitive prices. It will also save Ukraine hundreds of millions of Hryvnia so the country can buy more life-saving medicines with the same budget.”
Hemophilia is a mostly inherited genetic disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding. There are two main types of hemophilia: hemophilia A, which occurs due to not enough clotting factor VIII, and hemophilia B, which occurs due to not enough clotting factor IX. They are typically inherited from one's parents through an X chromosome with a nonfunctional gene.
In Ukraine (with Crimea and Sevastopol statistics absent) around 1900 adult and 600 child hemophilia patients are registered at the hospitals. 80-90% of children under 14 years old with severe hemophilia become disabled. The same applies to 100% of 18 y.o. patients with severe hemophilia. In Western Europe and North America countries, where preventive treatment of children with hemophilia is implemented, only 1-2% become disabled.Media inquiries: